ArticleJournal of inflammation research2025
Identifying and Diagnosing Lytic Cell Death Genes in Atherosclerosis Using Machine Learning and Bioinformatics.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lytic cell death (LCD) is gaining research attention in chronic inflammatory diseases such as atherosclerosis (AS). Our study investigates the role and mechanism of LCD in AS using machine learning and bioinformatics. Methods: We sourced gene expression data and single-cell sequencing from the GEO database. Differential analysis identified differentially expressed genes (DEGs), which were then intersected with LCD-related genes to determine LCD-associated DEGs (LCDEGs). Machine learning was used to screen characteristic LCDEGs, and an artificial neural network (ANN) model was developed. The diagnostic accuracy of the model was assessed using ROC curves. Results: The results demonstrated that the ANN model possesses a robust diagnostic ability in distinguishing between normal and AS cases, as well as identifying early and advanced stages. Unique AS subtypes were identified using a consensus clustering method. Two subtypes, C1 (non-immune subtype) and C2 (immune subtype), were delineated based on immune landscape analysis and gene set variation analysis functional enrichment. The chi-square test revealed that C1 was linked to early-stage (low-risk) atherosclerotic plaques, whereas C2 was associated with advanced-stage (high-risk) atherosclerotic plaques. At the single-cell level, LCDEG activity was calculated using AUCell and AddModuleScore. LCDEGs exhibited increased activity levels in macrophages within the initially classified cell subtypes. Moreover, they displayed higher activity in the "inflammation" subtype of specific macrophage subtype analysis. Conclusion: This study highlights the clinical potential of LCD in AS and suggests it involves a macrophage-mediated mechanism. We also experimentally identified and validated cytochrome B-245β chain (CYBB) as a potential biomarker for AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.